Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 15 Prince Arthur Avenue TORONTO ON M5R 1B2 |
Tel: | 1-416-5771443 |
Website: | https://www.antibethera.com |
IR: | See website |
Key People | ||
Daniel Legault President, Chief Executive Officer, Secretary, Director | Walter M. Macnee Vice Chairman of the Board | Alain S. Wilson Chief Financial Officer |
Scott Wilson Curtis Chief Operating Officer | Joseph Stauffer Chief Medical Officer | Ana Stegic Director - Clinical Operations | David James Vaughan Chief Development Officer |
Business Overview |
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company's pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429. |
Financial Overview |
For the nine months ended 31 December 2023, Antibe Therapeutics Inc revenues was not reported. Net loss before extraordinary items decreased 7% to C$15M. Lower net loss reflects Stock-based Compensation in SGA decrease of 68% to C$491K (expense), Stock-based Compensation in R&D decrease of 65% to C$287K (expense), Research and clinical trial costs decrease of 5% to C$6.8M (expense). |
Employees: | 11 as of Mar 31, 2023 |
Reporting Currency: | Canadian Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$19.91M as of Dec 31, 2023 |
Net annual income (TTM): | -$18.24M as of Dec 31, 2023 |
Free cash flow (TTM): | -$18.24M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 53,009,362 as of Apr 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |